Alkermes PLC said Wednesday it has entered into a clinical trial collaboration and supply agreement with Merck & Co. to evaluate nemvaleukin alfa in combination with Keytruda in comparison with investigator choice chemotherapy in patients with platinum-resistant ovarian cancer.
Under the terms of the agreement, Alkermes is responsible for conducting the Phase 3 study, which is planned to begin in the second half of 2021.
Nemvaleukin is Alkermes's novel investigational engineered interleukin-2 variant for immunotherapy.
Alkermes said nemvaleukin in combination with Keytruda has demonstrated antitumor activity in heavily pre-treated patients with platinum-resistant ovarian cancer in an ongoing study, with durable and deepening responses observed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.